Intest Res Search

CLOSE


Intest Res > Volume 21(2); 2023 > Article
Oh, Hong, Ham, Lee, Park, Yang, Yoon, Kim, Choi, Ye, and on behalf of the Korean Association for the Study of Intestinal Diseases: Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intest Res 2023;21(1):137-147
In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.
“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2).”

REFERENCES

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study. Intest Res 2023;21:137-147.
crossref pmid pdf
TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 1,485 View
  • 137 Download
We recommend


ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2024 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next